A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results
Christopher A. Yasenchak(Willamette Valley Cancer Institute and Research Center), Andres Forero‐Torres(Kirklin Clinic), Jonathan W. Friedberg(University of Rochester), Megan M. O’Meara(Seagen (United States)), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Beata Holkova(Virginia Commonwealth University), Robert Chen(AstraZeneca (United States)), Peter J. Rosen(Providence Health & Services), Ralph V. Boccia(Center for Cancer and Blood Disorders)
Cited by 5
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k